Reata Pharmaceuticals Inc. (RETA) Stock Biogen Deal Contestable

• RETA stock rallied 332.70% YTD and 603.03% in a year. 
• Biogen Inc. is in the process of acquiring Reata Pharma, but the deal needs to be made more explicit. 

Reata Pharmaceutical Inc. had to push earnings from August 8 to  August 14, 2023. Biogen Inc. is acquiring Reata and the RETA stock gained 89.02% in 3 months. The deal is still under process, and if Biogen walks out on the deal, it will have to pay Reata a termination fee of $301 Million. Also, if Reata terminates the agreement, it will have to pay Biogen about $264 Million. 

Reata Pharmaceuticals Inc. (RETA) Stock: Financial Analysis

In recent trading sessions, NASDAQ: RETA shares had a volume of 6.04 Million and had traded green in the last 5 sessions. The pharma company probably had to push the earnings date due to a going acquisition deal. Still, the forecast of the company’s financials for the fiscal year 2023 was revealed by experts. 

The revenue could fall by 42.60% in Q2, with an additional 14.80% drop in the next quarter. Analysts predict that the revenue could gain 2,351.70% compared to the previous financial year. When looking at the performance of the past five years, the earnings suffered by 33.80%. Still, the predictions state that revenue would jump to minus 4.30% in 2023. 

Biogen Inc.’s deal to acquire Reata Pharmaceutials Inc. for a premium of 58.9% at $172.50 per share in cash is under the crosshairs of the regulators. Many argue against the deal because of the following reasons. Was the price set by Biogen fair? Were Reata shareholders given complete information about the deal? 

Moreover, Reata’s SKYCLARYS is the first FDA-approved treatment for Friedreich’s ataxia (FA) in the United States. This development is a crucial point to consider in the deal. 

Reata Pharmaceutials Inc. (NASDAQ: RETA): Technical Analysis

At press time, RETA shares are trading at $167.11, falling 0.03%; previous close and open were at $167.16 and $167.48, respectively. The 52-week range is from $18.47 to $168.70, respectively. With a volume of $1.37 Million shares, the market cap is $6.275 Billion. 

The trailing twelve-month (TTM) earnings per share (EPS) is negative $9.73, showcasing weakness. Analysts placed a price target at $147.91 with an 11.5% downside and provided a 2.31 rating for “hold”. 

Reata Pharmaceuticals reported its last earning on May 10, 2023, where the reported revenue of $195K surpassed the estimated value of $117.143K by 10.08%. At the same time, the reported earnings of minus $3.14 per share failed to beat the expected value of negative $2.39 per share by 31.21%. This negativity caused the RETA stock to fall around 28%. 

The subsequent earnings, previously scheduled on August 8, are pushed to August 14, 2023. The revenue could be $22.175 Million, and earnings might be negative $0.482 per share. RETA stock rallied 60.13% in a month, 276.63% in six months, 332.70% YTD, and a whopping 603.03% in a year. 

Reata Pharmaceutical Inc. (RETA) Stock: Candle Exploration

RETA stock price action is overstretched, creating a vast gap zone on July 27, 2023. Previously, the stock price sustained these gaps and consolidated in the higher regions. However, this zone is more significant than the rest; the price could come down to $120.00 to fill the void. 

Customarily, the price action returns to fill the gap, though the timeline varies from stock to stock. If it manages to sustain itself, the jump price could enter and surpass the selling zone. But as the recent candles do not appear strong, the possibility of a rally is debatable. 

Disclaimer:

The views and opinions stated by the author, or any people named in this article, are for informational purposes only and do not establish financial, investment, or other advice. Investing in or trading crypto assets and stocks comes with a risk of financial loss.